Petrol protests may delay diesel reform
The UPA government came under intense pressure on Thursday from within the ruling coalition and protesters to roll back the steepest petrol price hike in the country's history, less than 24 hours after it took the unpopular decision cheered by investors. Full Article
Reuters Showcase
Bharti Inks Deal
India's top mobile phone carrier to buy 49 pct in Qualcomm India broadband venture Full Article
Facebook IPO Fallout
Four of Wall Street's main market makers' losses total at least $100 mln Full Article
Aiming To Crack China
India's Mahindra taps Korean arm to push brand in world's largest auto market Full Article
Reuters India Mobile
Get the latest news on the go. Visit Reuters India on your mobile device. Full Coverage
India's Sun Pharma, MedImmune settle on ethyol
MUMBAI |
MUMBAI Aug 3 (Reuters) - India's Sun Pharmaceutical Industries Ltd (SUN.BO) said on Monday it has settled a patent dispute with AstraZeneca (AZN.L)'s MedImmune unit for generic version of Ethyol, resolving all litigation between them.
Under the settlement, Sun Pharma can continue to sell its generic version of MedImmune's Ethyol in the United States, Sun said in a statement to the stock exchange.
Ethyol is used to reduce toxicities associated with certain cancer chemotherapy and radiotherapy. (Reporting by Bharghavi Nagaraju; Editing by Harish Nambiar)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters